Cargando…

Development of a New Tool to Assess the Quality of Life of Patients with Hand–Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study

Background Hand–foot syndrome (HFS) can result in significant deficits in health-related quality of life (HRQOL) and can lead to poor compliance, dose reduction, or interruption. This study was performed to assess the HRQOL with HFS on physical, psychological, social, and sexual aspects of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jagdish, Prathepa, Kaur, Navdeep, Kapoor, Akhil, Mandavkar, Sarika, Ramaswamy, Anant, Ostwal, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273316/ https://www.ncbi.nlm.nih.gov/pubmed/35833045 http://dx.doi.org/10.1055/s-0041-1735957

Ejemplares similares

Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
por: D’Souza, Anita, et al.
Publicado: (2020)

Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
por: Harris, Caleb, et al.
Publicado: (2019)

Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
por: Ramaswamy, Anant, et al.
Publicado: (2018)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2009)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2008)

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis
por: Ostwal, Vikas, et al.
Publicado: (2017)

Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study
por: Ostwal, Vikas, et al.
Publicado: (2021)

Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
por: Son, Hyun-Sook, et al.
Publicado: (2009)

Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)
por: Santhosh, Akhil, et al.
Publicado: (2022)

Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?
por: Kapoor, Akhil, et al.
Publicado: (2020)

Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
por: Saif, Muhammad W, et al.
Publicado: (2016)

Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity?
por: Caprez, Jennifer, et al.
Publicado: (2018)

Generalised Lichenoid Drug Eruption Accompanied by Hand-foot Syndrome Due to Capecitabine
por: Tamer, Funda, et al.
Publicado: (2018)

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient
por: Whorton, Allison E, et al.
Publicado: (2022)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022)

Treatment of Metastatic Colorectal Cancers in Resource-Constrained Low- and Middle-Income Countries (LMICS) Scenario—Outcomes, Practice Patterns, and Commentary on Treatment Costs
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation
por: de Queiroz, Marina Vieira Rodrigues, et al.
Publicado: (2022)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
por: Zielinski, Christoph, et al.
Publicado: (2016)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers
por: Ostwal, Vikas, et al.
Publicado: (2019)

Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report
por: Lee, Sehe-Dong, et al.
Publicado: (2007)

Henna Application in the Prevention of Capecitabine-Induced Hand-Foot Syndrome in Breast and Colorectal Cancer Patients
por: Kayikci, Emel Emine, et al.
Publicado: (2020)

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome – A literature review()
por: Nascimento, Anna Danielly Almeida do, et al.
Publicado: (2023)

An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?
por: Vasudevan, Biju
Publicado: (2010)

Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report
por: INOKUCHI, MASAFUMI, et al.
Publicado: (2014)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
por: Hiromoto, Shiori, et al.
Publicado: (2021)

Stevens-Johnson syndrome and concurrent hand foot syndrome during treatment with capecitabine: A case report
por: Ahn, Ha Rim, et al.
Publicado: (2021)

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)
por: Iimura, Yohei, et al.
Publicado: (2022)

Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report
por: Pande, Nikhil, et al.
Publicado: (2019)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
por: Hofheinz, R-D, et al.
Publicado: (2012)

Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach
por: Schmulenson, Eduard, et al.
Publicado: (2020)

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome
por: Watts, Katie, et al.
Publicado: (2022)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
por: Dranitsaris, George, et al.
Publicado: (2014)

Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center
por: Bose, Subhadeep, et al.
Publicado: (2017)

Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience
por: Pai, Trupti, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_870te73tkstgfivi70mqo8ud86